Premium
Digital Therapeutic Self‐Management Intervention in Adolescents With Migraine: Feasibility and Preliminary Efficacy of “Migraine Manager”
Author(s) -
Hommel Kevin A.,
Carmody Julia,
Hershey Andrew D.,
Holbein Christina,
KabboucheSamaha Marielle,
Peugh James,
Powers Scott
Publication year - 2020
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.13805
Subject(s) - migraine , medicine , physical therapy , acute migraine , self management , quality of life (healthcare) , baseline (sea) , intervention (counseling) , alternative medicine , psychiatry , placebo , nursing , oceanography , pathology , machine learning , geology , computer science
Objective The objective of this study was to design, code, and pilot test the feasibility and preliminary efficacy of a self‐management digital therapeutic tool for adolescents with migraine. Background Self‐management of migraine in adolescents is complex and has important implications for health outcomes. A comprehensive and accessible approach to self‐management is needed for youth with migraine, their parents, and clinicians. Methods An iterative co‐design process was used to develop and optimize the Migraine Manager's digital therapeutic self‐management tool. Subsequently, 40 adolescents, age 11‐18 years, were enrolled in an 8‐week single‐arm open label trial (N = 36 analyzed). The primary outcome was headache days. Results Usage data for Migraine Manager were similar to other health app usage data and feedback from participants was uniformly positive, indicating acceptable feasibility. Preliminary efficacy was demonstrated by a reduction in headache days from 17.2 ± 8.5 at baseline to 7.9 ± 7.2 at 8 weeks (95% CI, −13.0 to −7.8; P < .001). There was also statistically significant improvement in patient physical functioning quality of life reported by both patients (baseline = 55.7 ± 20.4; 8 weeks = 69.7 ± 21.9, P = .005) and parents (baseline = 58.5 ± 22.8; 8 weeks = 74.3 ± 18.1, P = .002), and in parent‐reported ingestion issues subscale of the adherence barriers scale from baseline to 8 weeks (baseline = 6.0 ± 2.6; 8 weeks = 5.2 ± 3.0, P = .020). Conclusions A self‐management digital therapeutic tool for adolescents with migraine can offer care to patients who might not otherwise receive such services. Migraine Manager demonstrated the feasibility and preliminary efficacy in this pilot trial, highlighting the potential beneficial impact of this tool. Larger controlled trials with long‐term follow‐up are needed to definitively determine the clinical efficacy of Migraine Manager.